Table 1.
Characteristics of included subjects and studies.
| Characteristics | |
| Sample size (median, range, IQR) | 21 (1-370, 81.5) |
| Confirmed Monkeypox (PCR) (n, %) | 1031/1512 (68.2) |
| Age (mean, SD) | 24.2 (19.4) |
| Sex: female (n, %) | 465/1031 (45.1) |
| Location of MPX treatment (n, %) | |
| Hospital | 331/419 (79.0) |
| Community | 88/419 (21.0) |
| Not stated | 612 |
| Country (k) | |
| USA | 6 |
| Nigeria | 5 |
| Democratic Republic of Congo | 5 |
| Republic of Congo | 2 |
| UK | 1 |
| Year of data collection (latest year, k): | |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2003 | 8 |
| 1985 | 1 |
| Study Design (k) | |
| Cohort | 12 |
| Cross-sectional | 2 |
| Case series | 4 |
| Case report | 1 |
| Retrospectivea | 7 |
| Prospectivea | 7 |
| Single centre | 11 |
| Multicentre | 7 |
| Unclear | 1 |
| Newcastle-Ottawa Scale Quality Assessment (k)b | |
| Low | 6 |
| Medium | 8 |
| High | 0 |
a
only applies to cohort and cross-sectional studies.
b
Based on 14 studies (Newcastle-Ottawa Scale used for cohort and cross-sectional studies only).